Advertisement

Topics

Kite assesses EU manufacturing options as it submits CAR-T therapy for review

07:19 EDT 4 Aug 2017 | BioPharma-Reporter

Kite Pharma has submitted the first CAR-T candidate axicabtagene ciloleucel to the EMA for review and says it is evaluating manufacturing options in Europe.

Original Article: Kite assesses EU manufacturing options as it submits CAR-T therapy for review

NEXT ARTICLE

More From BioPortfolio on "Kite assesses EU manufacturing options as it submits CAR-T therapy for review"

Quick Search
Advertisement